Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Nkarta Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Nkarta 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
JPRN-jRCT2031260309 Alixorexton Narcolepsy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2031260309, evaluating Alixorexton in Narcolepsy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Autolus Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Autolus Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
JPRN-jRCT2031260308 Alixorexton Narcolepsy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2031260308, evaluating Alixorexton in Narcolepsy: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Arcellx Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Arcellx 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
CTR20262629 TQA凝胶贴膏 Osteoarthritis, Knee Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into CTR20262629, evaluating TQA凝胶贴膏 in Osteoarthritis, Knee: design, endpoints, sponsor context, readout timing and white space.
Latest Hotspot
8 min read
NCT07700719 SHR-A1904 Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07700719, evaluating SHR-A1904 in Colorectal Adenocarcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07700667 Tislelizumab Unresectable Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07700667, evaluating Tislelizumab in Unresectable Esophageal Squamous Cell Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07708025 Oral iron supplementation Heart Failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07708025, evaluating Oral iron supplementation in Heart Failure: design, endpoints, sponsor context, readout timing and white space.
Latest Hotspot
8 min read
JPRN-jRCTs072250148 Percutaneous Spinal Cord Stimulation Supranuclear Palsy, Progressive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCTs072250148, evaluating Percutaneous Spinal Cord Stimulation in Supranuclear Palsy, Progressive: design, endpoints, sponsor context, readout timing and white space.
Latest Hotspot
8 min read
NCT07702851 Polatuzumab Vedotin-Piiq Diffuse large B-cell lymphoma recurrent Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07702851, evaluating Polatuzumab Vedotin-Piiq in Diffuse large B-cell lymphoma recurrent: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07701928 Daridorexant hydrochloride Sleep Initiation and Maintenance Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07701928, evaluating Daridorexant hydrochloride in Sleep Initiation and Maintenance Disorders: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.